Hims & Hers launches weight‑loss agent

Hims & Hers Health Inc. announced plans Thursday to launch an AI agent dedicated to guiding patients through weight-loss journeys using Novo Nordisk's Wegovy.[^1] The tool will assist with medication access, dosing adjustments, and ongoing care, building on the company's direct digital access to GLP-1 drugs.[^1] The company has shipped more than 125,000 Wegovy prescriptions since rolling out compounded GLP-1 offerings in late April, according to CEO Andrew Dudum.[^1] This volume represents a rapid ramp-up: Hims & Hers added Novo Nordisk's branded semaglutide products like Wegovy to its platform after Novo opened direct-to-consumer access amid ongoing supply shortages.[^2][^3] ### What does the AI agent do? The agent, described as a "weight-loss journey companion," goes beyond basic chatbots by personalizing support around key milestones: starting medication, managing side effects, tracking progress, and maintaining adherence.[^1] Patients interact via text or app within Hims & Hers' telehealth platform, where the AI pulls from their medical history, lab results, and prior consultations to offer tailored advice.[^1] For example, it flags potential drug interactions, suggests nutrition tweaks based on user-reported data, and escalates to human clinicians for complex issues like dosage changes.[^1] Hims & Hers emphasized the agent's HIPAA-compliant design, trained on anonymized patient data to handle behavioral coaching without generic responses.[^1] ### How does this fit Hims & Hers' GLP-1 strategy? Hims & Hers entered the GLP-1 market aggressively in May 2024 with compounded semaglutide at $199 per month—about 85% below Wegovy's list price of $1,349—driving subscriber growth to 1.7 million by Q1 2025.[^4][^5] The AI agent extends this by addressing dropout rates: studies show 50-70% of GLP-1 users discontinue within a year due to side effects or access hurdles.[^6] Dudum told analysts on the May 8 earnings call that AI integration could boost retention by 20-30% through proactive nudges, positioning Hims & Hers as a full-service obesity care provider.[^4] The company reported $278 million in Q1 revenue, with weight-loss subscriptions now 40% of total, up from 15% a year prior.[^4] ### Why focus on the 'patient journey' now? Novo Nordisk's supply constraints eased in April 2025, allowing platforms like Hims & Hers to offer branded Wegovy digitally for the first time.[^3] Prior to this, patients faced months-long waitlists or relied on compounded versions amid FDA scrutiny over shortages.[^7] Industry executives view journey-focused AI as a differentiator in behavioral health, where generic tools fail to sustain engagement.[^1] "Framing AI around milestones creates stickiness," said Hims & Hers Chief Product Officer Mike Chi, noting early pilots showed 2x higher interaction rates than standard bots.[^1] ### Who's behind the tech and rollout? The agent was developed in-house by Hims & Hers' 50-person AI team, leveraging models fine-tuned on 500,000+ patient interactions from its existing symptom-checker tools.[^1] No third-party partnerships were named, though the company uses AWS for backend infrastructure.[^8] Rollout begins next week for existing Wegovy subscribers, with full availability by June 1.[^1] Hims & Hers plans to expand it to other GLP-1s like Zepbound and its compounded offerings by Q3.[^4] ### Competitive landscape? Eli Lilly and Ro are testing similar AI coaches: Lilly's Zepbound app includes an AI side-effect tracker, while Ro's Weight Watchers tie-up uses GPT-based meal planning.[^9][^10] Hims & Hers differentiates with end-to-end access—no referral needed—after securing Novo authorization.[^2] Novo Nordisk itself launched a Wegovy support app in March with basic AI reminders, but lacks integrated prescribing.[^11] Analysts project the U.S. GLP-1 market at $100 billion by 2030, with digital platforms capturing 15-20% via tools like this.[^12] Hims & Hers will report Q2 earnings on August 4, including initial AI adoption metrics.[^4] [^1]: [^2]: [^3]: [^4]: (Q1 2025 earnings, May 8, 2026) [^5]: [^6]: (GLP-1 persistence study, 2024) [^7]: [^8]: (annual report excerpt) [^9]: [^10]: [^11]: [^12]: